Related Experiment Videos
(-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
Abstract:
Idiopathic Parkinson's disease may derive from the action of an environmental 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-like compound. Monoamine oxidase (MAO) B converts MPTP to an actual neurotoxin, 1-methyl-4-phenylpyridinium (MPP+) whilst prior administration of an MAO B inhibitor, (-)deprenyl, prevents the conversion. There is preliminary evidence that this drug can interrupt the pathological process in Parkinson's disease and prolong life expectancy. Thus, markers should be sought to identify the premorbid parkinsonian condition, prior to long-term (-)deprenyl treatment. Possibly approaches are by monitoring putative overactivity of the dopamine degrading enzymes, phenolsulphotransferase and MAO B, narrowing the field down further by PET-scan after administering a positron-emitting dopa analogue, 6-18F-labelled dopa.
Insights
Environmental toxins like MPTP may cause Parkinson's disease. Early detection using enzyme activity markers and PET scans could enable treatment with MAO B inhibitors, potentially slowing disease progression.
Area of Science:
- Neuroscience
- Environmental Toxicology
- Pharmacology
Background:
- Idiopathic Parkinson's disease (PD) may be linked to environmental neurotoxins, such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
- Monoamine oxidase B (MAO B) metabolizes MPTP into the potent neurotoxin 1-methyl-4-phenylpyridinium (MPP+).
- MAO B inhibitors, like (-)deprenyl, can block this conversion and show preliminary efficacy in PD treatment.
Purpose of the Study:
- To identify biomarkers for detecting premorbid Parkinson's disease.
- To explore strategies for early intervention with MAO B inhibitors prior to disease manifestation.
- To investigate methods for identifying individuals who might benefit from long-term (-)deprenyl treatment.
Main Methods:
- Monitoring enzymatic activity of phenolsulphotransferase and MAO B as potential markers.
- Utilizing Positron Emission Tomography (PET) scans with 6-18F-labelled dopa.
- Assessing the neurotoxic conversion of MPTP by MAO B and its inhibition by (-)deprenyl.
Main Results:
- Preliminary evidence suggests (-)deprenyl can interrupt the pathological process in Parkinson's disease.
- MAO B plays a crucial role in converting MPTP to its toxic form, MPP+.
- Overactivity of dopamine-degrading enzymes may serve as a premorbid marker.
Conclusions:
- Identifying individuals in the premorbid stage of Parkinson's disease is critical for effective early intervention.
- Monitoring MAO B and phenolsulphotransferase activity, alongside PET imaging, offers promising avenues for early PD detection.
- Early treatment with MAO B inhibitors like (-)deprenyl may halt disease progression and improve life expectancy.